Question · asked by 1 review
Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX): All‐cause mortality (n/N)
- Population
- Not specified
- Intervention
- Summary of findings: Comparison 3 ‐ deferiprone (DFP)
- Comparison
- deferasirox (DFX)
- Outcome
- All‐cause mortality (n/N)
Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX) All‐cause mortality (n/N) Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty). Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2023) · Cochrane Headline outcomes only | RD 0 | 1 study · 390 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.